Importer of Controlled Substances Application: Galephar Pharmaceutical Research, Inc., 23069-23070 [2017-10234]
Download as PDF
<![CDATA[
23069
Federal Register / Vol. 82, No. 96 / Friday, May 19, 2017 / Notices
Controlled substance
Drug code
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) .......................................................................................................................
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) ..............................................................................
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) ......................................................................................................
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ..................................................................
JWH-073 (1-Butyl-3-(1-naphthoyl)indole) ........................................................................................................................
Lysergic acid diethylamide ..............................................................................................................................................
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C–T–7) ..............................................................................................
3,4-Methylenedioxyamphetamine ....................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine .......................................................................................................................
3,4-Methylenedioxymethamphetamine ............................................................................................................................
MDPV (3,4-Methylenedioxypyrovalerone) .......................................................................................................................
Methylone (3,4-Methylenedioxy-N-methylcathinone) ......................................................................................................
Desomorphine .................................................................................................................................................................
Norlevorphanol ................................................................................................................................................................
Phencyclidine ...................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ..............................................................................................................
Noroxymorphone .............................................................................................................................................................
Sufentanil .........................................................................................................................................................................
Tapentadol .......................................................................................................................................................................
Fentanyl ...........................................................................................................................................................................
The company plans to manufacture
small quantities of the listed controlled
substances in bulk for distribution to its
customers.
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017–10231 Filed 5–18–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
SUPPLEMENTARY INFORMATION:
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Johnson
Matthey Pharmaceutical Materials, Inc.
ACTION:
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before July 18, 2017.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
Notice of application.
7019
7118
7122
7144
7173
7315
7348
7400
7404
7405
7535
7540
9055
9634
7471
9273
9668
9740
9780
9801
Drug code
Amphetamine ...................................................................................................................................................................
Methylphenidate ..............................................................................................................................................................
Nabilone ...........................................................................................................................................................................
Hydrocodone ...................................................................................................................................................................
Alfentanil ..........................................................................................................................................................................
Remifentanil .....................................................................................................................................................................
Sufentanil .........................................................................................................................................................................
asabaliauskas on DSK3SPTVN1PROD with NOTICES
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on
September 26, 2016, Johnson Matthey
Pharmaceutical Materials, Inc.,
Pharmaceutical Service, 25 Patton Road,
Devens, Massachusetts 01434 applied to
be registered as a bulk manufacturer of
the following basic classes controlled
substances:
Controlled substance
The company plans to utilize this
facility to manufacture small quantities
of the listed controlled substances in
bulk for distribution to its customers as
well as to conduct analytical testing in
support of the company’s primary
manufacturing facility in West Deptford,
New Jersey.
Schedule
1100
1724
7379
9193
9737
9739
9740
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
II
II
II
II
II
II
II
DEPARTMENT OF JUSTICE
[FR Doc. 2017–10233 Filed 5–18–17; 8:45 am]
Schedule
[Docket No. DEA–392]
Drug Enforcement Administration
BILLING CODE 4410–09–P
Importer of Controlled Substances
Application: Galephar Pharmaceutical
Research, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class, and applicants
DATES:
VerDate Sep<11>2014
19:15 May 18, 2017
Jkt 241001
PO 00000
Frm 00117
Fmt 4703
Sfmt 4703
E:\FR\FM\19MYN1.SGM
19MYN1
23070
Federal Register / Vol. 82, No. 96 / Friday, May 19, 2017 / Notices
therefore, may file written comments on
or objections to the issuance of the
proposed registration in accordance
with 21 CFR 1301.34(a) on or before
June 19, 2017. Such persons may also
file a written request for a hearing on
the application pursuant to 21 CFR
1301.43 on or before June 19, 2017.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix of subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on
November 10, 2016, Galephar
Pharmaceutical Research, Inc., #100
Carr 198, Industrial Park, Juncos, Puerto
Rico 00777–3873 applied to be
registered as an importer of
hydromorphone (9150), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance in finished
dosage form for clinical trials, research
and analytical purposes.
The import of this class of controlled
substance will be granted only for
analytical testing, research, and clinical
trials. This authorization does not
extend to the import of a finished FDA
approved or non-approved dosage form
for commercial sale.
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
19:15 May 18, 2017
Jkt 241001
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017–10234 Filed 5–18–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Whatever LLC
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class, and applicants
therefore, may file written comments on
or objections to the issuance of the
proposed registration in accordance
with 21 CFR 1301.34(a) on or before
June 19, 2017. Such persons may also
file a written request for a hearing on
the application pursuant to 21 CFR
1301.43 on or before June 19, 2017.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
Comments and requests for hearing on
applications to import narcotic raw
material are not appropriate. 72 FR 3417
(January 25, 2007).
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
DATES:
PO 00000
Frm 00118
Fmt 4703
Sfmt 4703
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on October
16, 2015, Whatever LLC, 4370 N.
Randall Street, Flagstaff, Arizona 86004
applied to be registered as an importer
of opium poppy (9650), a basic class of
controlled substance listed in schedule
II.
The company plans to import opium
poppy (9650), for dried floral decorative
arrangements. Approval of permit
application will occur only when the
registrant’s business activity is
consistent with what is authorized
under to 21 U.S.C. 952(a)(2).
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017–10243 Filed 5–18–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: American
Radiolabeled Chemicals
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before July 18, 2017.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
DATES:
E:\FR\FM\19MYN1.SGM
19MYN1
]]>Agencies
[Federal Register Volume 82, Number 96 (Friday, May 19, 2017)]
[Notices]
[Pages 23069-23070]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10234]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Galephar
Pharmaceutical Research, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class, and
applicants
[[Page 23070]]
therefore, may file written comments on or objections to the issuance
of the proposed registration in accordance with 21 CFR 1301.34(a) on or
before June 19, 2017. Such persons may also file a written request for
a hearing on the application pursuant to 21 CFR 1301.43 on or before
June 19, 2017.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
request for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix of subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on
November 10, 2016, Galephar Pharmaceutical Research, Inc., #100 Carr
198, Industrial Park, Juncos, Puerto Rico 00777-3873 applied to be
registered as an importer of hydromorphone (9150), a basic class of
controlled substance listed in schedule II.
The company plans to import the listed controlled substance in
finished dosage form for clinical trials, research and analytical
purposes.
The import of this class of controlled substance will be granted
only for analytical testing, research, and clinical trials. This
authorization does not extend to the import of a finished FDA approved
or non-approved dosage form for commercial sale.
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017-10234 Filed 5-18-17; 8:45 am]
BILLING CODE 4410-09-P
